Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER)

This study is not yet open for participant recruitment.
Verified October 2013 by Massachusetts General Hospital
Sponsor:
Collaborators:
New England Research Institutes
Information provided by (Responsible Party):
Ravi Thadhani, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01960153
First received: October 8, 2013
Last updated: October 9, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)